YORKSURe

  • Research type

    Research Study

  • Full title

    Early detection of bladder cancer in Yorkshire: Feasibility assessments for implementing a targeted study in populations with high disease specific mortality risk

  • IRAS ID

    302276

  • Contact name

    James Catto

  • Contact email

    j.catto@sheffield.ac.uk

  • Sponsor organisation

    University of Sheffield

  • ISRCTN Number

    ISRCTN34273159

  • Duration of Study in the UK

    1 years, 5 months, 31 days

  • Research summary

    Yorkshire has some of the lowest survival rates from bladder cancer in Britain. Improvements in survival could be delivered through earlier diagnosis by screening individuals at high-risk of dying from this cancer. The detection of non-visible blood (non-visible haematuria - NVH) in the urine could be a way to detect bladder cancer early in people without symptoms.

    Before starting a large early detection trial across Yorkshire, we need to understand the best method to find and test persons for bladder cancer, and how many cancers may exist. We will carry out the work necessary to answer these questions in three parallel studies:

    COHORT 1). We will send 2000 urine self-testing kits to screen-engaged participants of the Yorkshire Lung Screening Trial.

    COHORT 2). We will send 3000 urine self-testing kits to eligible men (65-80 years).

    Participants in these two cohorts will self-test their urine up to six occasions. Those with NVH detected in the urine will undergo further urine testing (for cancerous cells) and an ultrasound scan at a study clinic. Those with suspected cancer will be referred to their local hospital.

    COHORT 3). We will send urine self-testing kits to 1000 NHS patients being investigated for potential bladder cancer in the 2 week wait (2WW) pathway.

    These 3 cohorts will tell us how reliable urine self-testing is for detecting bladder cancer.

    All participants that self-test and non-responders in Cohort 2 (excluding those that opt-out or withdraw) will have information collected on them from the National Cancer Registration and Analysis Service (NCRAS) for 3 years after the end of the study. This information will be used to help assess the effectiveness of the urine self-testing.

    If the study results are promising, then there will be a much larger study in the future to look at urine screening in more people in Yorkshire.

  • REC name

    London - Riverside Research Ethics Committee

  • REC reference

    22/LO/0018

  • Date of REC Opinion

    28 Mar 2022

  • REC opinion

    Further Information Favourable Opinion